Why the study?
Optimal doses of RAAS inhibitors improve clinical outcomes in heart failure but can cause hyperkalemia, motivating an exploration of the incidence and predictors of hyperkalemia in a broad heart failure population.
Population
7,599 patients with heart failure in the CHARM Program
Comparison
Standard heart failure therapy plus candesartan (target 32 mg once daily) vs placebo
Design
Randomized trial
Follow-up
Median 3.2 years
Answers are grounded in this paper and cite their sources.
Alerts clinicians to hyperkalemia risk in HF; extends observational predictors but leaves optimal strategies open pending trials.
Objectives We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients. Background When used in optimal doses to treat patients with heart failure, renin-angiotensin-aldosterone system (RAAS) inhibitors improve clinical outcomes but can cause hyperkalemia. Methods Participants in the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) (n = 7,599) Program were randomized to standard heart failure therapy plus candesartan or placebo, titrated as tolerated to a target of 32 mg once daily with recommended monitoring of serum potassium and creatinine. We assessed the incidence and predictors of hyperkalemia associated with dose reduction, study drug discontinuation, hospitalization, or death over the median 3.2 years of follow-up. Results Independent of treatment assignment, the risk of hyperkalemia increased with age > or =75 years, male gender, diabetes, creatinine > or =2.0 mg/dl, K+ > or =5.0 mmol/l, and background use of angiotensin-converting enzyme inhibitors or spironolactone. Candesartan increased the rate of aggregate hyperkalemia from 1.8% to 5.2% (difference 3.4%, p < 0.0001) and serious hyperkalemia (associated with death or hospitalization) from 1.1% to 1.8% (difference 0.7%, p < 0.001), with hyperkalemia associated with death reported in 2 (0.05%) candesartan patients and 1 (0.03%) placebo patient. The benefit of candesartan in reducing cardiovascular death or heart failure hospitalization (relative risk reduction 16%, p < 0.0001) was uniform in these subgroups, as was the incremental risk of hyperkalemia. Conclusions The risk of hyperkalemia is increased in symptomatic heart failure patients with advanced age, male gender, baseline hyperkalemia, renal failure, diabetes, or combined RAAS blockade. Although these groups derive incremental clinical benefit from candesartan, careful surveillance of serum potassium and creatinine is particularly important.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: